3 Solar Panels Maker, Steel Wire Ropes Maker and Generic Medicines Maker Stocks With a Strong Future Roadmap: Saatvik Green Energy, Usha Martin and Marksans Pharma

Solar panel, wire rope and generic drug stocks bring together companies with a visible plan for the years ahead. Saatvik Green Energy, Usha Martin and Marksans Pharma cover a solar panels maker, a steel wire ropes maker and a generic medicines maker.

This list covers three solar panel, wire rope and generic drug stocks with complete current figures: Saatvik Green Energy, Usha Martin and Marksans Pharma. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Solar Panel, Wire Rope and Generic Drug Stocks?

Solar panel, wire rope and generic drug stocks are listed companies that make solar cells and modules, make steel wire ropes, wires and strands for mining, ports and infrastructure, and make generic tablets, capsules and liquids for regulated markets. Their earnings depend on solar installations, mining and infrastructure activity and export orders.

Solar Panel, Wire Rope and Generic Drug Stocks at a Glance

On valuation, Saatvik Green Energy and Marksans Pharma trade at a P/E below the industry P/E, while Usha Martin trades above it, which reflects the growth the market already expects. Readers comparing solar panel, wire rope and generic drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Solar Panel, Wire Rope and Generic Drug Stocks Have a Strong Roadmap in India?

Solar panel, wire rope and generic drug stocks have a strong roadmap in India because rapid solar capacity additions, steady mining and port activity and growing demand for affordable medicines keep widening the market for these companies.

• Solar panels. Utilities and homes add clean energy fast.
• Wire ropes. Mines and ports need strong steel ropes.
• Generic medicines. Affordable medicines reach more markets.

Why Saatvik Green Energy Features Among These Solar Panel, Wire Rope and Generic Drug Stocks

Among the solar panel, wire rope and generic drug stocks on this list, Saatvik Green Energy is a Haryana-based manufacturer of solar photovoltaic modules and cells that supplies utility-scale, commercial and rooftop solar projects.

The company has a return on equity of 26.2%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 4,934 crore. The stock trades at a P/E of 20.1, below the industry P/E of 43.9.

Revenue rose from Rs 618 crore in FY22 to Rs 4,588 crore in FY26, a compound annual growth rate of 65.1%. Net profit grew from Rs 217 crore in FY25 to Rs 357 crore in FY26, a rise of 64.5%.

Roadmap: The company is adding module and cell capacity to meet rising demand for locally made solar equipment and is building a more integrated production chain. India's solar capacity targets support a steady flow of orders.

What to watch: Track capacity additions, order book growth and solar policy support.

Why Usha Martin Features Among These Solar Panel, Wire Rope and Generic Drug Stocks

Among the photovoltaic, steel cable and tablet shares on this list, Usha Martin is a leading maker of wire ropes and other steel wire products used in mining, oil and gas, construction and infrastructure. It also runs an integrated steel operation that supports its wire business.

Revenue rose from Rs 2,723 crore in FY22 to Rs 3,760 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 291 crore in FY22 to Rs 491 crore in FY26, which works out to a compound annual growth rate of 13.9%.

In the June 2026 quarter, revenue grew 15.4% year on year to Rs 1,042 crore, while net profit rose 40.9% to Rs 142 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 14,230 crore. The stock trades at a P/E of 28.1, above the industry P/E of 22.4.

Roadmap: The company is growing its value-added wire rope and speciality product lines and exporting to many countries. Its own steel supply supports quality control and cost.

What to watch: Track wire rope volumes, export orders and demand from mining and infrastructure users.

Why Marksans Pharma Features Among These Solar Panel, Wire Rope and Generic Drug Stocks

Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.

In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.

Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.

Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

What to watch: Track export growth, new product approvals and plant utilisation.

Saatvik Green Energy vs Usha Martin vs Marksans Pharma on Key Financials

The table below sets the three solar panel, wire rope and generic drug stocks side by side on revenue, profit and margin, using reported figures.

Saatvik Green Energy posts the highest return on equity in this group at 26.2%. Saatvik Green Energy combines the largest FY26 revenue at Rs 4,588 crore with the fastest revenue growth, a 65.1% compound annual rate. A useful habit with solar panel, wire rope and generic drug stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Solar Panel, Wire Rope and Generic Drug Stocks

Every theme carries risks that deserve a check before any decision. For these solar panel, wire rope and generic drug stocks, the main points are: Long-term photovoltaic, steel cable and tablet shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Module prices. Solar equipment prices and policy support can change returns.
• Commodity prices. Selling prices follow global and domestic markets.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter solar panel, wire rope and generic drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Solar Panel, Wire Rope and Generic Drug Stocks

Solar panel, wire rope and generic drug stocks suit investors who prefer to study business strength before price moves. Saatvik Green Energy, Usha Martin and Marksans Pharma each have a clear plan to grow. Based on the 12 November 2026 close, Saatvik Green Energy trades at Rs 357, Usha Martin at Rs 488.8 and Marksans Pharma at Rs 320. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these solar panel, wire rope and generic drug stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track solar panel, wire rope and generic drug stocks, set price alerts and get research-backed stock ideas.

What are solar panel, wire rope and generic drug stocks?

Ans. Solar panel, wire rope and generic drug stocks are listed companies that make solar cells and modules, make steel wire ropes, wires and strands for mining, ports and infrastructure, and make generic tablets, capsules and liquids for regulated markets. Their earnings depend on solar installations, mining and infrastructure activity and export orders. This list looks at three of them, Saatvik Green Energy, Usha Martin and Marksans Pharma, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.

Which solar panel, wire rope and generic drug stocks are covered in this list?

Ans. This list covers Saatvik Green Energy, Usha Martin and Marksans Pharma. Based on the 12 November 2026 close, Saatvik Green Energy traded at Rs 357, Usha Martin at Rs 488.8 and Marksans Pharma at Rs 320. Their return on equity ranges from 13.8% to 26.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 65.1%.

Why do solar panel, wire rope and generic drug stocks have a strong future roadmap in India?

Ans. Solar panel, wire rope and generic drug stocks have a strong roadmap in India because rapid solar capacity additions, steady mining and port activity and growing demand for affordable medicines keep widening the market for these companies. The main drivers are as follows. Solar panels. Utilities and homes add clean energy fast. Wire ropes. Mines and ports need strong steel ropes. Generic medicines. Affordable medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Saatvik Green Energy performed financially?

Ans. Revenue rose from Rs 618 crore in FY22 to Rs 4,588 crore in FY26, a compound annual growth rate of 65.1%. Net profit grew from Rs 217 crore in FY25 to Rs 357 crore in FY26, a rise of 64.5%. The company has a return on equity of 26.2%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 4,934 crore. The stock trades at a P/E of 20.1, below the industry P/E of 43.9. Looking ahead, the company is adding module and cell capacity to meet rising demand for locally made solar equipment and is building a more integrated production chain. India's solar capacity targets support a steady flow of orders.

How has Usha Martin performed financially?

Ans. Revenue rose from Rs 2,723 crore in FY22 to Rs 3,760 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 291 crore in FY22 to Rs 491 crore in FY26, which works out to a compound annual growth rate of 13.9%. In the June 2026 quarter, revenue grew 15.4% year on year to Rs 1,042 crore, while net profit rose 40.9% to Rs 142 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 14,230 crore. The stock trades at a P/E of 28.1, above the industry P/E of 22.4. Looking ahead, the company is growing its value-added wire rope and speciality product lines and exporting to many countries. Its own steel supply supports quality control and cost.

How has Marksans Pharma performed financially?

Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

What risks should investors check before buying solar panel, wire rope and generic drug stocks?

Ans. Investors should check a few risks before buying solar panel, wire rope and generic drug stocks. Module prices. Solar equipment prices and policy support can change returns. Commodity prices. Selling prices follow global and domestic markets. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of solar panel, wire rope and generic drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.